Recently, mutations in the transcription factor CCAAT/ enhancer binding protein alpha (C/EBP␣) have been described in acute myeloid leukemia (AML). We performed a mutational analysis of the C/EBP␣ gene in the myelodysplastic syndromes and AML with antecedent MDS. No mutations were found in patients with refractory anemia (0/27), refractory anemia with ringed sideroblasts (0/7), refractory anemia with excess of blasts (RAEB 0/16) or chronic myelomonocytic leukemia (CMML 0/5). One out of 13 patients with RAEB-T/AML secondary to MDS showed a mutation in the C/EBP␣ gene. In this patient a 4 bp insertion disrupted codon 69 in one allele. This novel +1 frame shift is predicted to result in a truncated protein of 107 amino acids. However, the dominant protein translated was the C/EBP␣ isoform p30, which was previously shown to inhibit the DNA-binding and transactivation properties of C/EBP␣ p42. Interestingly this mutation could not be detected at diagnosis in the initial RAEB and RAEB-T stage. The mutation appeared at relapse after chemotherapy for RAEB-T. We conclude that the C/EBP␣ mutation was not essential for the initial blast accumulation. The emergence of a bast clone carrying a C/EBP␣ mutation at relapse indicates that this mutation may confer a growth advantage in a myeloid cell with an established differentiation block.
Introduction
Transcription factor CCAAT/enhancer binding protein alpha (C/EBP␣) is essential for granulocytic differentiation. 1 Targeted disruption of the C/EBP␣ gene in mice results in a complete block of granulocytic differentiation. 1 Overexpression of C/EBP␣ in the myeloid leukemia cell line U937 drives the cells along the granulocytic differentiation pathway. 2 C/EBP␣ transactivates a number of genes expressed in granulocytopoiesis including the genes for the receptor of granulocyte colony-stimulating factor (G-CSF) and the primary granule protein neutrophil elastase. 3, 4 Recently, dominant negative mutations in the C/EBP␣ gene have been described in acute myeloid leukemia (AML). 5 In eight out of 137 (5.8%) analyzed AML patients, nine different mutations were reported which result in changes of the amino acid sequence in the translated C/EBP␣ protein. In 5/137 (3.6%) AML cases, heterozygous mutations in the aminoterminus resulted in the translation of a truncated C/EBP alpha protein. In these cases, the p30 C/EBP␣ isoform, which lacks the transactivation domain 1 of C/EBP␣, was preferentially expressed and blocked full length C/EBP␣ DNA binding and transactivation.
5 C/EBP␣ mutations were found in AML M1, AML M2 without t (8;21) and one case of secondary AML. 5 Recently one C/EBP␣ mutation was reported in a series of 92 patients with myelodysplastic syndromes (MDS). 6 This patient was diagnosed as RAEB-T, which is classified as secondary AML according to WHO. 7 In order to determine the frequency of C/EBP␣ mutations in the myelodysplastic syndromes (MDS) and AML secondary to MDS, we used a PCR SSCP assay for the C/EBP␣ gene which is able to detect mutations which potentially occur only in subpopulations of cells. We hypothesized that C/EBP␣ mutations may be associated with blast accumulation in MDS. In 52 cases with MDS no mutations were identified. The emergence of a new heterozygous C/EBP␣ mutation was demonstrated in a secondary AML at relapse after chemotherapy for RAEB-T.
Materials and methods

Patients
Fifty-eight bone marrow samples from 52 patients initially diagnosed with a myelodysplastic syndrome and from 12 patients presenting with RAEB-T/secondary AML were taken from the iliac crest after informed consent. In seven patients, more than one bone marrow sample was obtained at different time points (Table 1 ). In three of these cases the disease had progressed. Two RA patients had progressed to RAEB, (Nos 1, 3) and one RAEB patient to AML/MDS (No. 47). Mononuclear cells were isolated by Ficoll-Hypaque density gradient centrifugation. Peripheral blood mononuclear cells were isolated from 25 healthy blood donors.
PCR-SSCP
DNA was isolated by standard procedures from mononuclear cells or from bone marrow smears (MDS samples from patient No. 47). In eight cases with secondary AML 1 g RNA was reverse transcribed into cDNA with AMV reverse transcriptase. Four overlapping fragments of the C/EBP␣ gene were amplified using 100 ng DNA template or 1 l cDNA. The PCR reaction mix contained 0.2 Ci [␣- PCR-SSCP was performed as described previously. 8, 9 One l PCR product was diluted with 9 l formamide loading buffer and heat denatured. Three l were then electrophoretically separated on a 6% polyacrylamide MDE gel (Biozym, Hessisch Oldendorf, Germany) with 10% glycerol at 8 W for 14 h. The gel was dried and exposed at −80°C to Kodak Biomax MR film (Kodak, Rochester, NY, USA) with intensifying screen. Shifted bands were excised and eluted in TE buffer overnight at room temperature. The eluted DNA was reamplified; sense and antisense strands were sequenced directly using the Perkin Elmer Big dye terminator cycle sequencing kit (PE Biosystems, Warrington, UK). The PCR reaction was analyzed on an ABI 310 sequencer. The human C/EBP␣ mRNA sequence, GenBank identification: 13632311, was used as the reference sequence to locate the position of polymorphisms and mutations.
Cloning and expression of the C/EBP␣ alleles of patient No. 47
Bone marrow blasts of patient No. 47 were enriched by Ficoll-Hypaque density gradient centrifugation and DNA was isolated. The complete coding sequence of the C/EBP␣ gene was amplified using the primer pair +19F (5Ј-GGA-GAACTCTAACTCCACCATG-Ј3) and Fragment 4-Reverse: (5Ј-CCTCACGCGCAGTTGCCCAT-3Ј) in a reaction mix containing 1× premix K (Epicentre Technologies), 200 M of each dNTP, 400 M of each primer, 1.25 l Failsafe enzyme mix and 100 ng genomic DNA in a total volume of 25 l. PCR was carried out with an initial denaturing step of 95°C for 10 min, followed by 35 cycles at 95°C for 30 s; 60°C for 30 s Leukemia and 72°C for 2 min. The PCR product was purified by gel extraction using the Quiaquick Gelextraction kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. 3 l of the eluted, purified PCR product was ligated into pCR3.1 cloning/mammalian expression vector (Eukaryotic TA expression Kit bidirectional, Invitrogen) and transformed into TOP 10 F' E. coli according to the manufacturer's protocol. Since the mutation introduces a new PvuI restriction site in the C/EBP␣ gene DNA from a representative number of clones (n = 36) were analyzed for the presence of the restriction site. Twelve of 36 clones carried the new restriction site at the expected position resulting in two bands of 2.0 kb and 4.3 kb (sense direction) or 2.7 kb and 3.6 kb (antisense direction) depending on the orientation of the insert. Five clones with PvuI restriction site and 10 clones without PvuI site were sequenced confirming the mutated, respectively the wild-type C/EBP␣ sequence. Wild-type and mutant C/EBP␣ were expressed in cos-1 cells. 48 hours after lipofectamine transfection a whole cell lysate of the cos cells was made with ice cold RIPA buffer containing protease inhibitors ((Complete) Roche Diagnostics, Mannheim, Germany). Western blot analysis was performed as described previously. 10 The blots were incubated overnight with 0.2 g/ml rabbit anti-C/EBP␣ antiserum (sc-61, Santa Cruz Biotechnology, CA, USA) or goat anti-C/EBP␣ (N-19, Santa Cruz Biotechnology) antiserum diluted in PBS containing 5% powdered milk. The primary antibodies were detected with donkey anti-rabbit horseradish peroxidase (HRP) or antigoat-HRP (1:5000). The complexes were developed with Supersignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) as described by the manufacturer, and detected by autoradiography.
Leukemia
Fluorescence in situ hybridization
Bone marrow smears were fixed in methanol/acetic acid (3:1), briefly air dried and dehydrated in increasing concentrations of ethanol. DNA was denaturated by incubating the slides in 70% formamide, 2 × SSC pH 7.0 at 70°C for 2 min. Slides were transferred into ethanol (−20°C). The FITC-labelled ␣-satellite probe specific for the centromeric region of chromosome 8 (Roche Diagnostics, Mannheim, Germany) was used for hybridization to the denatured DNA. The reaction was performed overnight at 37°C in a humidified atmosphere. After hybridization the cells were washed twice in 0.25 × SSC, pH 7.0 at 72°C for 5 min each. The nuclear DNA was counterstained with propidium-iodide/antifade (1:1). The number of chromosome 8 copies/cell was analyzed with a fluorescence microscope. 500 cells were evaluated on each slide.
Results
Fifty-eight bone marrow samples from 52 patients initially diagnosed with a myelodysplastic syndrome and from 12 patients presenting with RAEB-T/secondary AML were analyzed for mutations in the C/EBP␣ gene by PCR-SSCP and direct sequencing. The patient characteristics are listed in Table 1 . Seven patients were analyzed repeatedly at different time points. In three cases the disease had progressed between the sample dates (Nos 1, 3, 47). Two silent base pair changes were repeatedly found in the MDS bone marrow samples. To identify frequent polymorphic sequence variations in the C/EBP␣ gene in the German population we performed the same analysis on DNA extracted from peripheral leukocytes of 25 healthy blood donors. The first polymorphism (base pair: 840 G>T amino acid: T230T) was found in 17/64 (26%) of MDS and AML/MDS cases and 4/25 (16%) of controls, the second polymorphism (base pair 723 C>T amino acid: H191H) was found in 4/64 patients (6%) and 2/25 controls (8%) (Figure 1 ). The frequency of these polymorphic changes did not significantly differ between controls and patients. No C/EBP␣ mutations were identified in the DNA samples from 52 MDS patients (RA (0/27), RA-RS (0/7), CMML (0/5), RAEB (0/16)). In addition four samples with RAEB-T according to FAB classification did not have a CEBP␣ mutation (0/4).
11
One mutation was identified in nine samples from patients with secondary AML (>30% blasts) following MDS. This patient had relapsed 4. months after chemotherapy with cytosine arabinoside, idarubicin and etoposide (ICE regimen) for RAEB-T. A 4 bp insertion, a tandem duplication of ATCG bps 352-355 resulted in a frame shift mutation (Figure 1 ). The frame shift introduces a stop at codon 108. Interestingly, the insertion described here leads to a +1 frame shift as opposed to a +2 frame shift in all cases reported so far. This difference results in a different position of the stop codon in the new reading frame. In a +1 frame shift, the truncated protein is predicted to be smaller (107 amino acids vs 159 amino acids). The second protein predicted to be translated from the new mRNA is the C/EBP␣ p30 isoform (Figure 2) .
Having identified the mutation, we isolated DNA from bone marrow slides of the same patient obtained at different time points: at diagnosis (RAEB), 6 weeks later (RAEB-T), after chemotherapy in morphological complete remission (CR) and at relapse (initially analyzed time point). Representative morphology is depicted in Figure 3b . Interestingly, we found no mutation at the RAEB and RAEB-T stage as well as in CR after chemotherapy. The mutation emerged at relapse 4. months later (initially analyzed sample). Bone marrow morphology showed 16% and 25% blasts at the stages RAEB and RAEB-T (no C/EBP␣ mutation) and 36% at relapse with secondary AML (C/EBP␣ mutation). Both samples without C/EBP␣ mutation showed a severe dysgranulopoiesis with 58% of the myeloid cells maturing beyond the promyelocyte stage. In comparison, the sample with C/EBP␣ mutation showed a significantly impaired maturation with only 17% of myeloid cells Table 2 .
Leukemia beyond the promyelocyte stage (Table 2 ). Since the patient had a trisomy 8 as a single chromosomal aberration at diagnosis we compared the frequency of trisomy 8 cells by fluorescence in situ hybridization on bone marrow smears at the RAEB, RAEB-T and sAML stage. Trisomy 8 cells were found with a frequency of 28%, 32% and 23%, respectively.
To determine the frequency of the mutated allele in this sample we PCR cloned the C/EBP␣ gene from the DNA template. The ATCG insertion introduces a new PvuI restriction site into the coding sequence. Twelve out of 36 clones carried the PvuI site indicating that approximately 66% of the cells carried a heterozygous mutation. This percentage is close to the percentage of blast cells in the mononuclear cell fraction of the sample. To exclude a different mutation in the second allele we sequenced 10 clones without PvuI restriction site. All clones had the wild-type C/EBP␣ sequence. Although much less likely, we cannot exclude the possibility that 33% of cells carried the ATCG insert in both alleles. Both mutant and wild-type alleles were expressed in cos 1 cells. Western blot analysis showed the dominant expression of C/EBP␣ p30 isoform from the mutated allele (Figure 4) . Using an antiserum directed against the aminoterminus of the C/EBP␣ protein we were unable to detect the expression of the predicted truncated protein. The wild-type allele expressed almost exclusively the C/EBP␣ p42 isoform.
Discussion
In addition to fusion genes, mutations of myeloid transcription factors contribute to the molecular pathogenesis of acute myelogenous leukemia. Mutations have been described in the genes encoding for the transcription factors MLL, AML 1 and most recently C/EBP␣. 5, [15] [16] [17] The functional consequences of aminoterminal frame shift mutations of the C/EBP␣ gene have been elegantly characterized.
5 As opposed to the full length C/EBP␣ protein, the p30 isoform translated from the mutated allele was shown to be incapable of inducing differentiation when expressed in a myeloid leukemia cell line.
5 Since a C/EBP␣ mutation was described in a case of secondary AML, we analyzed the frequency of these mutations in a population of MDS patients with different FAB subtypes and different degrees of blast accumulation assuming that C/EBP␣ mutations may play a role at the stage of transformation towards AML. Although the sensitivity of the SSCP approach does not allow the detection of all mutations, our results confirm that C/EBP␣ mutations either do not occur or are rare in MDS. In our series one AML patients with antecedent MDS showed a mutation of the C/EBP␣ gene. An aminoterminal frame shift mutation was observed when the patient relapsed with secondary AML after chemotherapy. The same mutation was not detected in two bone marrow samples taken from the same patient before chemotherapy at diagnosis (RAEB, 16% myeloblasts) and 6 weeks later (RAEB-T/sAML, 25% myeloblasts). This implies that blast accumulation was initialy independent of a mutation in the CEBP␣ gene. At the time of
Figure 4
Western blot analysis of proteins expressed from the mutated C/EBP␣ allele (patient No. 47) and the wild-type C/EBP␣ allele. relapse, 4. months later, the clone carrying the mutation became dominant suggesting a growth advantage in vivo. In addition, less maturation was observed. A detailed analysis of the allelic frequency confirmed the high percentage of cells with at least one mutated C/EBP␣ allele at relapse. Although cells without C/EBP␣ mutation (eg normal lymphocytes) contaminated the sample, the demonstration of a wild-type C/EBP␣ sequence in 10 clones which did not carry the ATCG insertion suggests that the second allele was not mutated (heterozygosity). However, we can not exclude the unlikely possibility that both alleles aquired the identical mutation.
The mutation may have been induced by chemotherapy. Alternatively, a small subclone carrying the mutation prior to chemotherapy had a survival advantage during the exposure to the cytostatic drugs.
We confirm the enhanced translation of the C/EBP␣ isoform p30 from an allele carrying a frame shift mutation in the 5Ј part of the gene. 5 We were unable to detect the aminoterminal truncated protein. Possibly, this polypeptide was unstable in cos cells.
The C/EBP␣ p30 isoform was previously characterized as a transcriptional activator lacking antimitotic activity. 18 Full length C/EBP␣ was shown to have antiproliferative activity in different cell types including hepatocytes and adipocytes. 19, 20 Growth suppression is mediated by a direct repression of E2F-DP1 regulated transcription. 21 C-myc was recently identified as a crucial C/EBP␣ target gene in myeloid differentiation which is negatively regulated by the formation of a C/EBP␣/E2F-DP1 complex. 22 A defective negative regulation of E2F-DP1 mediated transcription, eg of the c-myc gene, by the p30 C/EBP␣ isoform or a mutated C/EBP␣ protein is a possible mechanism for the growth advantage of the affected clone. Interestingly, the patient with C/EBP␣ mutation had an additional copy of chromosome 8, the locus of the c-myc gene. 23 At relapse, the clone with trisomy 8 was still present raising the possibility that this clone acquired the mutation.
In conclusion, our data confirm that mutations in transcription factor C/EBP␣ are rare in MDS and can be a late event in the clonal evolution from MDS towards AML.
